GIVE BACK
Help raise awareness and funds for vital care, support and research through our partnership with the 2022 Walk to End Alzheimer’s
About Our Partnership
Xponential Growth Solutions and Fiduciary Education are proud to partner with the 2022 Walk to End Alzheimer's®, raising funds to support the Alzheimer’s Association in their mission to provide education and support to the millions who face dementia every day, while advancing critical research toward methods of treatment, prevention and, ultimately, a cure.
How to Get Involved:
Encourage professional peers to participate in the 2022 Walk to End Alzheimer's®
Make a direct contribution on behalf of your local team, company or organization
Donate your $150 registration fee for the 2022 Tampa Fiduciary Summit
Why Support The Alzheimer's Association Walk to End Alzheimer's®
An estimated 50 million people worldwide are living with dementia. In the United States alone, more than 6 million have Alzheimer’s, and over 11 million are providing unpaid care. Held annually in more than 600 communities nationwide, the Alzheimer's Association Walk to End Alzheimer's® is the world's largest fundraiser for Alzheimer's care, support and research. This inspiring event calls on participants of all ages and abilities to join the fight against the disease. Participants are encouraged to raise critical funds that allow the Alzheimer’s Association to:
About the Alzheimer’s Association
Use of Funds
-
• Online message boards through ALZConnected®.
• Support groups, connecting those facing the disease with a network of help in their community.
• A free nationwide 24/7 Helpline (800.272.3900) offering information and referrals.
-
• Currently investing over $250M to more than 750 projects in 39 countries.
• Accelerates study focused on the relationship between lifestyle habits and cognitive function by funding and implementing clinical trials such as the U.S. POINTER Study.
• Leads the field in research around risk reduction by investing in studies such as SPRINT MIND, the first randomized clinical trial to demonstrate that aggressive treatment of blood pressure can significantly reduce the occurrence of mild cognitive impairment (MCI).
-
• Helps pass landmark legislation such as the National Alzheimer's Project Act, which mandated a national plan to fight Alzheimer's.
• Drives bipartisan support for federal Alzheimer's and dementia research funding, bringing the current annual total to $2.8 billion.
• Ensures that individuals living with dementia, regardless of age, have access to critical care and support services through legislation such as the Older Americans Act.
